Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy.
Principal investigators Dr. Aaron Nagiel, MD, PhD, at Children’s Hospital of Los Angeles, and Dr. Lesley Everett, MD, PhD, MPhil, at the Oregon Health Sciences… Read More »Clinical researchers on X-linked retinoschisis (XLRS) reports the dosing of a first patient in a phase 1 / 2 study.
Researchers at the Department of Ophthalmology, University of California, Irvine and the Structural Biology Research Centre, Vrije Universiteit Brussels, Belgium, have reported the use of… Read More »US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 14th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »September 14th, 2023 “EURETINA-Brief”© Issue No. 278
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***